IBO Key Statistics, Chart & Performance
The current stock price of IBO is 0.4718 USD. In the past month the price decreased by -16%.
IBO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IBO.
IBO Financial Highlights
Over the last trailing twelve months IBO reported a non-GAAP Earnings per Share(EPS) of -3.58. The EPS decreased by -509.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -201.86% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IBO Forecast & Estimates
IBO Ownership
About IBO
Company Profile
Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.
Company Info
IMPACT BIOMEDICAL INC
1400 Broadfield Blvd., Suite 130
Houston TEXAS US
Employees: 2
Phone: 15852321500
IMPACT BIOMEDICAL INC / IBO FAQ
What does IMPACT BIOMEDICAL INC do?
Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.
What is the current price of IBO stock?
The current stock price of IBO is 0.4718 USD. The price decreased by -1.5% in the last trading session.
Does IBO stock pay dividends?
IBO does not pay a dividend.
What is the ChartMill rating of IMPACT BIOMEDICAL INC stock?
IBO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the market capitalization of IBO stock?
IMPACT BIOMEDICAL INC (IBO) has a market capitalization of 49.36M USD. This makes IBO a Nano Cap stock.